spacer
home > ict > winter 2021 > innovation in paediatric trials: conducting study visits at home
PUBLICATIONS
International Clinical Trials

Innovation in Paediatric Trials: Conducting Study Visits at Home


Patient participation in paediatric clinical trials involves the entire family, which presents unique challenges for both subjects and researchers. Logistical challenges on the family, such as transportation, childcare for other children, and balancing the substantial commitments of time and effort, often result in lengthy recruitment times and narrower patient populations for paediatric clinical trials. These same challenges also make evaluability, patient retention, and treatment compliance a struggle.

Fortunately, recent innovations in trial designs are addressing some of these barriers to recruitment and participation. Their new technologies and procedures help alleviate burdens for the subjects and their families without compromising the integrity of clinical trial procedures or the measurement of endpoints.

The Paediatric Patient Journey

To conceptualise the patient journey in the paediatric research space, imagine a parent of three children who agrees to have one child participate in a clinical trial. The challenges involved in simply getting to the clinic may mean excusing them from school, taking time off work, scheduling a babysitter for the other two children, or herding all three children into the car and finding ways to keep them entertained while at the clinic.

Families may also face additional challenges, such as changing or unstable housing, financial concerns, unreliable transportation, and changing phone numbers (1). These barriers and more can lead to poor treatment compliance or visit attendance during the course of the trial, or even to early withdrawal from the study

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jamie Wardynski, MBA, is a Director of Clinical Operations atPaidion Research. Jamie has 10 years’ experience in operational delivery of clinical trials, including the recent implementation of a decentralised clinical trial in the paediatric research space.

jamie.wardynski@paidion.com


Kumar Ilangovan, MD, is a board-certified paediatrician, and clinical informatics physician serving as Medical Monitor atPaidion Research. He has worked both clinically and on multiple public and health services research studies spanning 20 years.

kumar.ilangovan@paidion.com


Jordan Godwin is a member of the American Medical Writers Association and a consultant Medical Writer at Paidion Research, where she writes and edits regulatory documents for paediatric clinical trials.

jordan.godwin@paidion.com


Betsy Reid is Co-Founder and Chief Operating Officer of Paidion Research. Betsy has 25 years’ experience in executive management of operations within academic, pharma, and CRO industries.

betsy.reid@paidion.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion

ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk A/S (“Novo Nordisk”), whereby Novo Nordisk will acquire Emisphere, on a cash-free, debt-free basis, for $1.35 billion in cash. The consideration to be paid per share will depend on the amount of cash and debt at closing, but the Company currently estimates it to be approximately $7.82 per share based on approximately 170.9 million fully diluted shares outstanding. This price represents a premium of approximately 17% over the volume-weighted average Emisphere share price for the five trading days ending on November 5, 2020.
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement